Dana sits in an exam room, frustrated but curious.
She started a GLP-1 medication because her weight had crept up after menopause, even though she was doing “all the right things.” She expected appetite changes. She expected slower digestion. She expected the scale to move.
What she didn’t expect was all of the other things that happened.
- Her cravings quieted.
- Her blood pressure improved.
- Her joint pain eased.
- Her alcohol intake dropped because wine suddenly sounded less interesting.
- Her labs started looking better.
- And then she read a headline saying GLP-1 drugs might be linked to lower breast cancer risk.
That’s when her question changed.
Instead of asking, “Are these just weight loss drugs?” she started asking, “What else are these medications doing?”
And that’s what the real conversation is now.
GLP-1 medications are not magic. They are not a moral shortcut (although I used to think that). They are not for everyone. And they don’t replace food, movement, sleep, strength training, or basic metabolic care.
But the data are getting harder to ignore.
These medications may affect many systems that matter deeply for women in midlife and beyond:
- Blood sugar
- Insulin signaling
- Inflammation
- Appetite regulation
- Brain reward pathways
- Cardiovascular risk
- Kidney health
- Liver fat
- Sleep apnea
- Possibly cancer biology
The keyword is “possibly.” Especially when we talk about cancer.
So let’s look at what we know, what we do not know, and why this matters for women who want to protect their healthspan, not just lose weight.
What Are GLP-1 Drugs?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your body naturally makes, mostly in the gut, in response to food.
GLP-1 helps regulate:
- Insulin release
- Glucagon suppression
- Blood sugar stability
- Appetite
- Satiety
- Gastric emptying
- Communication between the gut and brain
GLP-1 receptor agonists are medications that mimic or enhance this pathway.
Common examples include:
- Semaglutide: Ozempic, Wegovy, Rybelsus
- Liraglutide: Victoza, Saxenda
- Dulaglutide: Trulicity
- Tirzepatide: Mounjaro, Zepbound
- Retatrutide: investigational, not FDA approved as of this writing, but coming
Tirzepatide is technically a dual GIP/GLP-1 receptor agonist. Retatrutide is even broader. It targets GIP, GLP-1, and glucagon receptors.
The Breast Cancer Data That Came Out This Month
The most attention-grabbing new data came from studies presented at the 2026 American Society of Clinical Oncology meeting.
The biggest headline: GLP-1 use was associated with lower breast cancer risk.
One retrospective analysis from the University of Pennsylvania included about 110,000 women ages 45 to 80. Women taking GLP-1 medications were about 30% to 35% less likely to develop breast cancer compared with women not taking these medications.
That’s an attention getter.
This doesn’t prove that GLP-1 drugs prevent breast cancer, but it can show an association. So we need more study about this.
Things we don’t know about the women in the study are whether they had:
- More medical follow-up
- Better diabetes care
- More weight loss
- Improved insulin resistance
- Lower inflammation
- Other lifestyle or medication differences
Still, this finding is worth paying attention to because it fits with what we already know about breast cancer risk, especially after menopause.
Why Breast Cancer Risk May Be Linked to Metabolic Health
After menopause, body fat becomes a more important source of estrogen production through aromatase activity. This does not mean estrogen is “bad.” But excess adipose tissue, especially visceral fat, can contribute to a more inflammatory and insulin-resistant internal environment.
That matters because breast cancer risk may be influenced by:
- Insulin resistance
- Chronic inflammation
- Excess visceral fat
- Higher postmenopausal estrogen production from adipose tissue
- Immune dysfunction
- Oxidative stress
- Poor metabolic flexibility
This is where GLP-1 medications become interesting beyond weight loss.
They may improve the terrain.
In plain English: they may help shift the body away from a high-insulin, high-inflammation, metabolically stressed state which may influence some of the pathways that affect cancer risk.
Breast Cancer Survival and Progression Signals
The June 2026 ASCO data did not stop at breast cancer incidence.
Another study involving about 27,000 breast cancer patients found that adding weight loss drugs to standard breast cancer treatment was associated with about a 30% lower risk of death.
A third study, led by Cleveland Clinic researchers, looked at more than 12,000 patients with several cancers, including breast, lung, colorectal, and liver cancer. GLP-1 users were less likely to progress to stage 4 disease compared with patients using another class of diabetes drugs.
These are not randomized trials proving that GLP-1 medications treat cancer or prevent recurrence. But the consistency of the signal across multiple studies is what makes researchers pay attention.
It raises important questions:
- Are GLP-1s reducing cancer risk because people lose weight?
- Are they lowering insulin and inflammation enough to affect tumor biology?
- Are they changing immune signaling?
- Are there direct effects on certain tumor cells?
- Could they improve tolerance of treatments like aromatase inhibitors by improving metabolic symptoms?
We certainly don’t have all the answers yet, but we have enough reason to take a deeper dive.
Proposed Mechanisms: How Could GLP-1s Affect Cancer Biology?
The proposed mechanisms are not proven, but they make biologic sense.
Possible pathways include:
- Lower insulin levels: High insulin can act as a growth signal in the body. Improving insulin sensitivity may reduce some growth-promoting signals.
- Reduced inflammation: Chronic inflammation is involved in cancer development and progression.
- Weight and visceral fat loss: Less visceral fat may mean lower inflammatory cytokines and improved hormone signaling.
- Improved adipokines: Fat tissue releases signaling molecules that can affect metabolism and inflammation.
- Immune modulation: GLP-1 drugs may affect immune pathways, though this area is still early.
- Epigenetic effects: Some researchers suspect GLP-1 medications may influence gene expression patterns related to inflammation and tumor growth.
- Lower alcohol intake: If GLP-1s reduce alcohol cravings in some people, that could indirectly lower risk for cancers linked with alcohol use.
- Better metabolic resilience: Improved blood sugar, blood pressure, liver fat, and cardiovascular risk may help the whole body function better during illness and treatment.
This is not one pathway. It is a web.
And that is exactly why this conversation belongs in women’s health.
Want to create a custom longevity health plan?
You’re in the right place.
I can help you with a functional approach to midlife women’s health including hormone balance, gut health, autoimmune issues, bone health, heart health and more!
GLP-1s and Other Obesity-Related Cancers
The breast cancer data are new, but the cancer conversation did not start this month.
A 2024 JAMA Network Open study looked at more than 1.6 million patients with type 2 diabetes and compared cancer risk among people using GLP-1 receptor agonists, insulin, or metformin.
Compared with insulin, GLP-1 use was associated with lower risk for several obesity-associated cancers, including:
- Colorectal cancer
- Endometrial cancer
- Gallbladder cancer
- Liver cancer
- Ovarian cancer
- Pancreatic cancer
- Esophageal cancer
- Meningioma
- Multiple myeloma
That does not mean GLP-1s are cancer-prevention drugs. It means they may reduce risk in people whose cancer risk is strongly tied to metabolic dysfunction.
What About Cardiovascular and Kidney Benefits?
This is where the evidence is stronger.
Semaglutide has been shown to reduce major cardiovascular events in adults with overweight or obesity and established cardiovascular disease, even in people without diabetes.
For years, obesity treatment was treated like a cosmetic issue. The cardiovascular data changed that conversation.
GLP-1 medications have also shown kidney benefits, especially in people with type 2 diabetes and chronic kidney disease. In the FLOW trial, semaglutide reduced major kidney disease events, cardiovascular death, and kidney-related death.
These are human clinical outcome data, not just lab theories.
For midlife women, this matters because cardiovascular disease remains the leading cause of death in women, with menopause being a metabolic transition point. Insulin resistance, visceral fat, blood pressure, lipids, inflammation, and sleep can all shift.
This is why I keep saying: midlife weight gain is not just about jeans fitting differently. It is a cardiometabolic signal.
What About GLP-1s and Depression?
The best human signal right now is that GLP-1 drugs may be associated with less worsening of depression and anxiety, especially in people with type 2 diabetes, obesity, or metabolic dysfunction.
A 2026 Swedish registry study published in The Lancet Psychiatry looked at almost 95,000 people with depression or anxiety who were also using diabetes medications. Semaglutide was associated with:
- 42% lower risk of worsening mental health
- 44% lower risk of worsening depression
- 38% lower risk of worsening anxiety
- 47% lower risk of worsening substance use disorder
Liraglutide had a smaller benefit, while exenatide and dulaglutide did not show the same signal.
So what might be behind these results? Better glucose control, weight loss, improved body image, reduced alcohol intake, lower inflammation, and better physical health could all contribute. Experts commenting on the study specifically warned that it should not yet be interpreted as proof of a direct depression treatment effect.
There is also broader mental health safety reassurance. In January 2026, the FDA asked drugmakers to remove suicidal ideation warnings from GLP-1 weight-loss drug labels after reviewing 91 placebo-controlled trials with 107,910 participants**.** The FDA did not find increased risk of suicidal thoughts, anxiety, depression, irritability, or psychosis compared with placebo.
GLP-1s and Addiction: The “Food Noise” Clue
One of the most fascinating areas of GLP-1 research is addiction.
Many patients taking GLP-1 medications report that “food noise” gets quieter. But some also report less interest in alcohol, nicotine, shopping, gambling, or other compulsive behaviors.
That does not mean GLP-1s are addiction cures. They are not approved for addiction treatment.
But early human data are intriguing.
A small randomized trial published in JAMA Psychiatry studied semaglutide in 48 adults with alcohol use disorder. Participants receiving semaglutide drank less in a lab setting, had fewer heavy drinking days over time, and reported reduced cravings compared with placebo.
There are also observational studies suggesting GLP-1 users may have lower rates of alcohol-related problems, opioid overdose, cannabis use disorder, and other substance-related outcomes.
The proposed mechanism involves reward signaling.
GLP-1 receptors are found in brain areas involved in appetite, motivation, and reward. These medications may turn down the intensity of dopamine-driven craving signals. In plain language: the “I need it now” voice may get quieter. This has enormous implications if future trials confirm it.
But for now, GLP-1s should not replace established addiction treatments such as counseling, recovery programs, naltrexone, acamprosate, buprenorphine, methadone, or other evidence-based therapies.
This is an add-to-the-toolbox possibility, not a replacement for what’s already out there.
Why Hormones Matter in This Conversation
For women in perimenopause and menopause, GLP-1 medications sit inside a much bigger hormone story.
During the menopause transition, women may experience:
- More insulin resistance
- More visceral fat gain
- Poorer sleep
- More cravings
- Higher cortisol burden
- Changes in lipids
- Loss of muscle
- Loss of bone
- More inflammation
- More anxiety or mood changes
So when a woman says, “I gained weight overnight,” she is not being dramatic.
Her physiology changed.
GLP-1s may help some women manage the metabolic part of that shift. But they do not replace a full midlife plan.
A smart plan still needs:
- Adequate protein (non-negotiable)
- Strength training (also non-negotiable)
- Sleep support
- Stress regulation
- Hormone assessment when appropriate
- Lipid and cardiovascular risk testing
- Blood sugar and insulin testing
- Gut health support
- Muscle and bone protection
Otherwise, we risk chasing scale weight while missing the real goal: durable healthspan.
Who Might Benefit From This Conversation?
A GLP-1 discussion may be worth having with a qualified clinician if you have:
- Type 2 diabetes
- Prediabetes with significant insulin resistance
- Obesity or overweight with cardiometabolic risk
- Fatty liver disease or MASH
- Obstructive sleep apnea with obesity
- Cardiovascular disease and excess weight
- Postmenopausal weight gain with rising metabolic risk
- Strong family history of cardiometabolic disease
- Cancer survivorship concerns plus metabolic dysfunction
This does not mean everyone should take one.
It means some women deserve a thoughtful, individualized conversation instead of shame, fear, or internet noise.
Who Should Be More Cautious?
GLP-1 medications are not right for everyone.
Caution is especially important for people with:
- Personal or family history of medullary thyroid cancer
- MEN2 syndrome
- History of pancreatitis
- Gallbladder disease
- Severe GI motility problems
- Active eating disorder
- Pregnancy or plans for pregnancy
- Frailty, sarcopenia, or high fall risk
- Unexplained weight loss
- Complex cancer treatment plans without oncology input
And if you are in active cancer treatment, this is absolutely a discussion for your oncology team. Do not freestyle this one.
The Bottom Line
The GLP-1 story is no longer just about weight loss.
The strongest human data already support benefits in:
- Type 2 diabetes
- Weight management
- Cardiovascular risk reduction
- Kidney protection in high-risk patients
- Obstructive sleep apnea in adults with obesity
The emerging data suggest possible benefits in:
- Breast cancer risk reduction
- Cancer progression
- Cancer survival
- Alcohol use disorder
- Broader substance-use outcomes
- Liver fat and metabolic inflammation
- Brain reward pathways
But here is where we keep our feet on the ground:
- Association is not causation.
- Weight loss may explain part of the benefit.
- Direct drug effects are possible but not fully proven.
- Long-term safety still matters.
- Muscle, bone, and nutrition need protection.
- These medications should be used with strategy, not panic or vanity.
GLP-1s may be helping us see something bigger: metabolism is not separate from cancer risk, brain health, hormone health, cardiovascular health, or cravings.
It is all connected.
And midlife women deserve care that understands that.
If you are wondering whether your weight gain, blood sugar, cravings, inflammation, sleep, hormones, or long-term health risks are connected, they probably are.
The answer is not to chase the latest headline.
The answer is to connect the dots.
Book a Clarity Call and let’s talk about what your body is trying to tell you.
FAQ
Are GLP-1 drugs proven to prevent breast cancer?
No. The newest data are observational. They show an association between GLP-1 use and lower breast cancer risk, but they do not prove that GLP-1 drugs prevent breast cancer.
Can breast cancer survivors take GLP-1 medications?
Sometimes, but this should be discussed with the oncology team. The decision depends on cancer type, treatment plan, metabolic health, nutrition status, weight history, muscle mass, and medication tolerance.
Do GLP-1s work beyond weight loss?
Yes, in some areas the evidence is strong. GLP-1 drugs have human clinical data supporting benefits for blood sugar, cardiovascular risk, kidney outcomes, and obstructive sleep apnea in specific populations. Cancer and addiction data are promising but still emerging.
Can GLP-1 drugs treat addiction?
Not yet. They are not approved for addiction treatment. Early human studies suggest semaglutide may reduce alcohol intake and cravings, but larger trials are needed.
References
Badve, S. V., et al. (2024). Effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes: A meta-analysis of randomized trials. The Lancet Diabetes & Endocrinology.
Gregory, A. (2026, June 2). Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest. The Guardian.
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Tirzepatide/retatrutide trial investigators. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. The New England Journal of Medicine.
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. The New England Journal of Medicine.
Mishra, M. (2026, June 3). GLP-1 drugs may have a beneficial effect across many types of cancer. Reuters.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. The New England Journal of Medicine.
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine.
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024). Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Network Open.
Dr. Anna Garrett is a menopause expert and Doctor of Pharmacy. She helps women who are struggling with symptoms of perimenopause and menopause find natural hormone balancing solutions so they can rock their mojo through midlife and beyond. Dr. Anna is the author of Perimenopause: The Savvy Sister’s Guide to Hormone Harmony. Order your copy at www.perimenopausebook.com.
Dr. Anna is available for 1-1 consultations. Find out more at www.drannagarrett.com/lets-
